Extensive changes in liver gene expression induced by Hereditary Tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4- trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC)

Journal of Hepatology

Volumn 39, Issue 6, 2003, Pages 901-909

  Luijerink, Marjanka C ^a   Jacobs, Saskia M M ^a   Van Beurden, Ellen A C M ^a   Koornneef, Leander P ^a   Klomp, Leo W J ^a   Berger, Ruud ^a   Van Den Berg, Inge E T ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

2 (2 Nitro 4 trifluoromethylbenzoyl) 1,3 cyclohexanedione (NTBC); Fumarylacetoacetate hydrolase; Hepatocellular carcinoma; Liver damage; Liver gene profiling; Suppression subtractive hybridization

Indexed keywords

CYCLOHEXANE DERIVATIVE; FUMARYLACETOACETASE; NITISINONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC CODE; GENETIC DISORDER; LIVER CELL; LIVER CELL CARCINOMA; LIVER INJURY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SECRETION; RNA PROCESSING; SIGNAL TRANSDUCTION; TYROSINEMIA;

EID: 0347504717     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(03)00433-1     Document Type: Article

References (29)

1. van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 1994;20:1187-1191.
2. Mitchell GA, Grompe M, Lambert M, Tanguay RM. Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill; 2001. p. 1777-1805.
3. Kvittingen EA. Hereditary tyrosinemia type I - an overview. Scand J Clin Lab Invest Suppl 1986;184:27-34.
4. Laberge C, Lescault A, Tanguay RM. Hereditary tyrosinemias (type I): a new vista on tyrosine toxicity and cancer. Adv Exp Med Biol 1986;206:209-221.
5. Jorquera R, Tanguay RM. The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion. Biochem Biophys Res Commun 1997;232:42-48.
6. Jorquera R, Tanguay RM. Cyclin B-dependent kinase and caspase-1 activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis. FASEB J 1999;13:284-298.
7. Kubo S, Sun M, Miyahara M, Umeyama K, Urakami K, Yamamoto T, et al. Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors. Proc Natl Acad Sci USA 1998;95:9552-9557.
8. Sun MS, Hattori S, Kubo S, Awata H, Matsuda I, Endo F. A mouse model of renal tubular injury of tyrosinemia type 1: development of de Toni Fanconi syndrome and apoptosis of renal tubular cells in Fah/Hpd double mutant mice. J Am Soc Nephrol 2000;11:291-300.
9. Jorquera R, Tanguay RM. Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. Hum Mol Genet 2001;10:1741-1752.
10. Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992;340:813-817.
11. Holme E, Lindstedt S. Non-transplant treatment of tyrosinemia. Clin Liver Dis 2000;4:805-814.
12. Grompe M, al-Dhalimy M, Finegold M, Ou CN, Burlingame T, Kennaway NG, et al. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev 1993;7:2298-2307.
13. Ruppert S, Kelsey G, Schedl A, Schmid E, Thies E, Schutz G. Deficiency of an enzyme of tyrosine metabolism underlies altered gene expression in newborn liver of lethal albino mice. Genes Dev 1992;6:1430-1443.
14. Kelsey G, Ruppert S, Beermann F, Grund C, Tanguay RM, Schutz G. Rescue of mice homozygous for lethal albino deletions: implications for an animal model for the human liver disease tyrosinemia type 1. Genes Dev 1993;7:2285-2297.
15. Grompe M, Lindstedt S, al-Dhalimy M, Kennaway NG, Papaconstantinou J, Torres-Ramos CA, et al. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat Genet 1995;10:453-460.
16. al-Dhalimy M, Overturf K, Finegold M, Grompe M. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I. Mol Genet Metab 2002;75:38-45.
17. Ruppert S, Boshart M, Bosch FX, Schmid W, Fournier RE, Schutz G. Two genetically defined trans-acting loci coordinately regulate overlapping sets of liver-specific genes. Cell 1990;61:895-904.
18. Haber BA, Chuang E, Lee W, Taub R. Variable gene expression within human tyrosinemia type 1 liver may reflect region-specific dysplasia. Hepatology 1996;24:65-71.
19. Diatchenko L, Lau YF, Campbell AP, Chenchik A, Moqadam F, et al. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci USA 1996;93:6025-6030.
20. Altschul SF, Madden TL, Schärfer AA, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997;25:3389-3402.
21. Holme E, Lindstedt S. Tyrosinaemia type I and NTBC (2-(2-nitro-4- trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis 1998;21:507-517.
22. Nebert DW, Roe AL, Dieter MZ, Solis WA, Yang Y, Dalton TP. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem Pharmacol 2000;59:65-85.
23. Endo F, Kubo S, Awata H, Kiwaki K, Katoh H, Kanegae Y, et al. Complete rescue of lethal albino cl4CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway. J Biol Chem 1997;272:24426-24432.
24. Stoner E, Starkman H, Wellner D, Wellner VP, Sassa S, Rifkind AB, et al. Biochemical studies of a patient with hereditary hepatorenal tyrosinemia: evidence of glutathione deficiency. Pediatr Res 1984;18:1332-1336.
25. Mulders TM, Bergman DJ, Poll-The BT, Smit GP, Breimer DD, Mulder GJ, et al. Abnormal glutathione conjugation in patients with tyrosinaemia type I. J Inherit Metab Dis 1997;18:473-485.
26. Vasiliou V, Buetler T, Eaton DL, Nebert DW. Comparison of oxidative stress response parameters in newborn mouse liver versus simian virus 40 (SV40)-transformed hepatocyte cell lines. Biochem Pharmacol 2000;59:703-712.
27. 2 stimulon in Saccharomyces cerevisiae. J Biol Chem 1998;273:22480-22489.
28. Lee J, Godon C, Lagniel G, Spector D, Garin J, Labarre J, et al. Yap1 and Skn7 control two specialized oxidative stress response regulons in yeast. J Biol Chem 1999;274:16040-16046.
29. Gasch AP, Spellman PT, Kao CM, Carmel-Harel O, Eisen MB, Storz G, et al. Genomic expression programs in the response of yeast cells to environmental changes. Mol Biol Cell 2000;11:4241-4257.